Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2020-04-02 | James R. Meyers, age 55, has served as a member of our Board of Directors since November 2019. Mr. Meyers was appointed to the Compensation Committee effective April 1, 2020 and to the Nominating and Corporate Governance Committee effective January 2020. The following table sets forth certain information regarding the compensation of each non-employee director for service as a member of the Board of Directors during 2019. Mr. Meyers received total compensation of $254,758. |
| 2021-04-02 | James R. Meyers, age 56, has served as a member of our Board of Directors since November 2019. He has over 30 years of commercial leadership experience in the biotechnology industry. Since November 2020, Mr. Meyers has served as President and Chief Executive Officer of IntraBio Ltd., a privately-held biopharmaceutical company. Previously, Mr. Meyers held positions of increasing responsibility at Gilead Sciences, Inc., or Gilead, from 1996 to February 2018, most recently as Gilead’s Executive Vice President of Worldwide Commercial Operations from November 2016 to February 2018, where he was responsible for global commercial activities, including pricing and market access in North America, Europe, Middle East, Australia and Japan. Mr. Meyers joined Gilead in 1996 and successfully led 25 product launches in seven different therapeutic areas over a 22-year period, including 11 brands with peak annual revenue greater than $1 billion. Prior to Gilead, Mr. Meyers held positions of increasing responsibility with Zeneca Pharmaceuticals and Astra USA. He currently serves on the board of directors of two other public biopharmaceutical companies, Arbutus Biopharma Corporation and CytomX Therapeutics, Inc., and he remains an active advisor to several major biopharmaceutical companies. Mr. Meyers was appointed to the Audit Committee effective September 30, 2020 to replace Dr. Stephen G. Dilly, a former member of the Board who resigned from the Board and Audit Committee effective September 30, 2020. Mr. Meyers was appointed to the Compensation Committee effective April 1, 2020. The Audit Committee consists of three directors: Mr. Carey, Mr. Meyers and Ms. Ramasastry. Mr. Carey serves as the Chair of this committee. The Compensation Committee consists of three directors: Mr. Meyers, Dr. Smith and Mr. Zakrzewski. Mr. Zakrzewski serves as Chair of this committee. Mr. Meyers received total compensation of $289,574 in 2020. |
| 2022-04-01 | James R. Meyers, age 57, has served as a member of our Board of Directors since November 2019. The Audit Committee consists of three directors: Mr. Carey, Mr. Meyers and Ms. Ramasastry. The Compensation Committee consists of three directors: Dr. Hillan, Mr. Meyers and Dr. Smith. The following table sets forth certain information regarding the compensation of each non-employee director for service as a member of the Board of Directors during 2021. Mr. Meyers total compensation was $270,562. |
| 2023-04-17 | James R. Meyers, age 58, has served as a member of our Board of Directors since November 2019. ... During 2022, Mr. Meyers served on the Compensation Committee. |
| 2024-04-19 | James R. Meyers, age 59, has served as a member of our Board of Directors since November 2019. ... Audit Committee members include Mr. Meyers. ... Compensation Committee members include Mr. Meyers. ... Director compensation table shows James R. Meyers total compensation as $78,656. |
Data sourced from SEC filings. Last updated: 2026-02-03